Skip to content

Author

Xin-Nan Xu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Targeting LOXL4-driven matrix stiffening with acetyldigoxin restores CD8+ T cell function in lung cancer

Extracellular matrix (ECM) stiffness is known to impair T cell function, yet the underpinning molecular cascade remains undefined. This paper investigates the role of lysyl oxidase–like 4 (LOXL4) in ECM stiffening and CD8+ T cell function in lung cancer. Loxl4 knockout and mouse recombinant LOXL4 protein systems, along...

Xu-Yu Gu, Yi-Fei Zhu, Li Xu et al. · 0 citations
Open access Aug 2026

Toripalimab combined with chemotherapy in the treatment of primary tracheal squamous cell carcinoma: a phase II proof-of-concept study

Background Despite immunotherapy advancements for many solid cancers, role of first-line immunotherapy for tracheal malignancies is uncertain. This study aimed to evaluate the efficacy and safety of toripalimab with chemotherapy for initially-unresectable locally-advanced tracheal squamous cell carcinoma (SCC). Methods...

Jie Dai, Xin-Yun Fang, Xin-Sheng Zhu et al. · 0 citations
Open access Sep 2026

Targeting NCAPG with Arundanine Suppresses Neutrophil/NET-Mediated Immune Evasion and Enhances CD8+ T Cell Function in Lung Squamous Cell Carcinoma

It is found that NCAPG was significantly upregulated in LUSC, and NCAPG depletion markedly impaired LUSC cell proliferation, migration, and invasion while promoting apoptosis, and targeting NCAPG with Arundanine represents a promising therapeutic strategy to overcome immune evasion and sensitize LUSC to PD-1 blockade.

Xu-Yu Gu, Dong-Ning Lu, Ming Deng et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.